



# Gab2 and Gab3 Redundantly Suppress Colitis by Modulating Macrophage and CD8<sup>+</sup> T-Cell Activation

Zhengqi Wang<sup>1†</sup>, Tamisha Y. Vaughan<sup>1†</sup>, Wandi Zhu<sup>1</sup>, Yuhong Chen<sup>2</sup>, Guoping Fu<sup>2</sup>, Magdalena Medrzycki<sup>1</sup>, Hikaru Nishio<sup>3</sup>, Silvia T. Bunting<sup>4</sup>, Pamela A. Hankey-Giblin<sup>5</sup>, Asma Nusrat<sup>3,6</sup>, Charles A. Parkos<sup>3,6</sup>, Demin Wang<sup>2</sup>, Renren Wen<sup>2</sup> and Kevin D. Bunting<sup>1\*</sup>

<sup>1</sup> Division of Hem/Onc/BMT, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, United States, <sup>2</sup> BloodCenter of Wisconsin, Milwaukee, WI, United States, <sup>3</sup> Department of Pathology, Emory University, Atlanta, GA, United States, <sup>4</sup> Department of Pathology, Children's Healthcare of Atlanta, Atlanta, GA, United States, <sup>5</sup> Department of Veterinary Science, Pennsylvania State University, University Park, PA, United States, <sup>6</sup> Department of Pathology, University of Michigan, Ann Arbor, MI, United States

## OPEN ACCESS

### Edited by:

Kai Fang,  
University of California, Los Angeles,  
United States

### Reviewed by:

Roslyn Kemp,  
University of Otago, New Zealand  
Mary A. Markiewicz,  
University of Kansas Medical Center,  
United States

### \*Correspondence:

Kevin D. Bunting  
Kevin.bunting@emory.edu

<sup>†</sup>These authors have contributed  
equally to this work

### Specialty section:

This article was submitted to  
Inflammation,  
a section of the journal  
Frontiers in Immunology

**Received:** 19 October 2018

**Accepted:** 22 February 2019

**Published:** 18 March 2019

### Citation:

Wang Z, Vaughan TY, Zhu W, Chen Y, Fu G, Medrzycki M, Nishio H, Bunting ST, Hankey-Giblin PA, Nusrat A, Parkos CA, Wang D, Wen R and Bunting KD (2019) Gab2 and Gab3 Redundantly Suppress Colitis by Modulating Macrophage and CD8<sup>+</sup> T-Cell Activation. *Front. Immunol.* 10:486. doi: 10.3389/fimmu.2019.00486

Inflammatory Bowel Disease (IBD) is a multi-factorial chronic inflammation of the gastrointestinal tract prognostically linked to CD8<sup>+</sup> T-cells, but little is known about their mechanism of activation during initiation of colitis. Here, Grb2-associated binding 2/3 adaptor protein double knockout mice (Gab2/3<sup>-/-</sup>) were generated. Gab2/3<sup>-/-</sup> mice, but not single knockout mice, developed spontaneous colitis. To analyze the cellular mechanism, reciprocal bone marrow (BM) transplantation demonstrated a Gab2/3<sup>-/-</sup> hematopoietic disease-initiating process. Adoptive transfer showed individual roles for macrophages and T-cells in promoting colitis development *in vivo*. In spontaneous disease, intestinal intraepithelial CD8<sup>+</sup> but much fewer CD4<sup>+</sup>, T-cells from Gab2/3<sup>-/-</sup> mice with rectal prolapse were more proliferative. To analyze the molecular mechanism, reduced PI3-kinase/Akt/mTORC1 was observed in macrophages and T-cells, with interleukin (IL)-2 stimulated T-cells showing increased pSTAT5. These results illustrate the importance of Gab2/3 collectively in signaling responses required to control macrophage and CD8<sup>+</sup> T-cell activation and suppress chronic colitis.

**Keywords:** inflammatory bowel disease, colitis, Grb2-associated binding protein, effector CD8<sup>+</sup> T-cell, CD4<sup>+</sup> T-cell, macrophage, intraepithelial lymphocyte

## INTRODUCTION

The healthy gut has strong mechanisms in place to promote tolerance and control inflammation in response to environmental triggers such as infection and bacterial products. When this inflammation is not resolved, chronic uncontrolled inflammation of the intestine results in inflammatory bowel disease (IBD) (1). There are two major types of IBD in humans. Ulcerative colitis is primarily a disease of the colon and rectum, with inflammation and ulceration of mucosa and submucosa. In contrast, Crohn's disease affects the small intestine and colon, typically involving transmural inflammation, ulceration, and fistulae. Human IBD is a complex disorder resulting from the combination of genetic predisposition, environmental triggers, and the loss of integrity of the mucosal immune system. The genetic susceptibility is higher in Crohn's disease than in ulcerative

colitis in humans, although these diseases have indistinguishable phenotypes in mouse models of colitis. Intestinal bacteria also play a major role in the pathogenesis of chronic immune mediated intestinal inflammation and certain knockout mice such as IL-10<sup>-/-</sup> strains require the presence of enteric bacteria in order to initiate colitis (2).

In humans, genome-wide association studies have provided important evidence for genes involved in IBD pathology. Clusters of variants associated with human IBD include loss of epithelial barrier function, increased effector cell responses, changes in translation and metabolism, and immune regulatory cell defects. Numerous animal models of mucosal inflammation have validated several major categories of variants capable of dysregulating immune responses in mice (3, 4). While many of these involve the epithelium and loss of barrier function, less is known about cell intrinsic changes in hematopoietic cells, especially CD8<sup>+</sup> T-cells which are emerging as important regulators of human IBD (5) but are not well-characterized in this regard. Animal models on the role of T-cells in colitis development have also largely focused on CD4<sup>+</sup> T-cells. Interestingly, a “guilt-by-association” study by Lee et al. (6) reported on a major connecting node of signaling involving the Grb2 adaptor protein in Crohn’s disease. Therefore, in this study we set out to analyze a potential novel linkage between Grb2 and CD8<sup>+</sup> T-cells.

Although Grb2 has been well-characterized in immune signaling, Grb2-associated binding proteins have not. Grb2-associated binding protein 2 (Gab2) was first cloned in 1998 (7) as the second of 3 members of the family that share a Pleckstrin homology domain and regulate the PI3K-mTOR pathway through interactions with the p85 subunit of PI3K. This pathway was important to study because clinically effective drugs have been generated to members of the pathway and their roles in modulating macrophage and T-cell activation have been described (8–12). It is known that mTOR is a central sensor of nutrient availability in T-cells and that activation of mTOR is a sensitive regulator of metabolism, promoting CD8 maturation (13), T-bet expression, and the CD122 target gene in an IL-15 dependent manner (14). mTORC1 inhibition inhibits T-bet and CD122 expression but preserves memory development by promoting Eomes expression in a dosage-dependent manner (14–17). Since mTORC1 inhibits mTORC2 through negative feedback, selective regulation CD8 T-cell differentiation is achieved (18). Rictor (mTORC2) activity drives glycolytic effector T-cells (19) and Rictor deficiency promotes a memory phenotype (20).

Gabs form signalosomes and interact with additional partners including Grb2 and SHP-2 to bring together positive and negative regulators of immune cell activation, although the physiological significance is not defined. Gab2<sup>-/-</sup> mice have some impaired cellular functions (21–25) but Gab3<sup>-/-</sup> mice have no defined phenotypes alone (26) despite high Gab3 expression in several immune cell types (27–29). Most studies of Gab2 function in T-cells have focused on T-cell receptor (TCR) activation in cell lines (30–34). IL-2 and IL-15 signaling through IL-2Rβ results in Gab2 phosphorylation (35). However, it is not known whether Gab2 has any functional role in IL-2/IL-15 signaling.

Interestingly, Gab-like molecular mimicry by *Helicobacter pylori* CagA virulence factor (36–38) has been consistently inversely related to human IBD (39–41). Gain-of-function of CagA driven gastritis in mice and humans seems to have a protective effect against colitis perhaps through immune evasion (42) raising the possibility that Gab adaptor proteins may have a similar function to maintain normal steady-state immune homeostasis. Therefore, we set out to determine whether Gabs are immune suppressive *in vivo* and to identify the underlying cellular and molecular mechanism. To investigate potential complementary function of these two Gabs, novel Gab2/3<sup>-/-</sup> mice were generated. A fraction of these double knockout, but not single knockout, mice developed rectal prolapses and suffered from diarrheas driven by macrophages and predominately CD8<sup>+</sup> T-cells, supporting a novel major redundant role for Gab2/3 in immune cell inactivation required for the suppression of colitis.

## MATERIALS AND METHODS

### Antibodies and Mice

All antibodies used are listed in **Table S1**. All animal studies were conducted in compliance with relevant local guidelines, such as the US Department of Health and Human Services Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committees (IACUCs) at Emory University and the BloodCenter of Wisconsin. Gab2<sup>-/-</sup> mice were generously provided by Dr. Toshio Hirano (Osaka University) and backcrossed 9 generations to C57BL/6J. Gab3<sup>-/-</sup> mice were generously provided by Dr. Larry Rohrschneider (Fred Hutchinson Cancer Research Center) and backcrossed 11 generations to C57BL/6. Double knockout Gab2/3<sup>-/-</sup> mice were initially generated by intercrossing heterozygote Gab2<sup>+/-</sup>-Gab3<sup>+/-</sup> mice and maintained by both heterozygote and homozygote crosses. Animals were housed under a standard day/night cycle with free access to food and water. Progeny were genotyped for Gab2 and Gab3 deletion by PCR and the expected genotype ratios were obtained. Wild-type (WT) C57BL/6J mice (000664), enhanced green fluorescent protein (GFP) transgenic mice (003291), B6 (Cg)-Rag2<sup>tm1.1Cgn</sup>/J Rag2<sup>-/-</sup> mice (008449), and B6.SJL-Ptprc<sup>a</sup> Pepc<sup>b</sup>/BoyJ mice (002014) were all from the Jackson Laboratory (Bar Harbor, ME).

### Peripheral Blood Hematology, Endpoints for Euthanasia, and Macroscopic Colon Inflammation Scoring of Mice With Spontaneous Active Colitis

Following puncture of either the facial vein or the retro-orbital venous sinus, WT, Gab2<sup>-/-</sup>, Gab3<sup>-/-</sup>, and Gab2/3<sup>-/-</sup> mice peripheral blood was collected in a heparinized capillary tube (Thermo Fisher Scientific, Norcross, GA). Mouse hematology was determined using a HemaTrue Hematology Analyzer (Heska, Loveland, CO). Mice showing loss of 25% body weight, major organ failure, rectal prolapse, hind limb paralysis, or clinical or behavioral signs described above for more than 24 h after appropriate intervention (and no response) were euthanized by the CO<sub>2</sub> method according to the IACUC

protocol. Macroscopic colon inflammation score (0–9): Colon weight was scored as follows: 200–275 mg = 0; 276–350 mg = 1; 351–425 mg = 2; 426–550 mg = 3. Colon thickness was scored as follows: none = 0; mild = 1; moderate = 2; severe = 3. Stool consistency was scored as follows: hard = 0; mostly hard but some soft = 1; mostly soft but some hard = 2; diarrhea = 3.

### Lipocalin-2 Assay on Stool Samples

Quantification of stool lipocalin-2 was performed as previously described (43). Briefly, fresh stool samples were collected, weighed, and reconstituted in PBS containing 0.1% Tween 20 at a concentration of 100 mg/ml. Samples were crushed and vortexed to obtain homogenous suspensions. These suspensions were then centrifuged at 12,000 rpm, 4°C for 10 min. The supernatants were collected and used for further analysis. The level of lipocalin-2 was determined using murine lipocalin-2/NGAL DuoSet ELISA kit (R&D Systems, Minneapolis, MN).

### Spontaneous Colitis Histology and Scoring

Histological examination was performed on whole colons of experimental and control mice. Microscopy was performed at room temperature using an Olympus BX41 microscope with an OlymDP21 camera (Olympus America Inc., Center Valley, PA). CellSens imaging software (downloaded from <https://www.olympus-lifescience.com>) was used for image acquisition. Histological parameters were quantified in a blinded fashion using parameters as previously described (44, 45) with some modification for spontaneous development (developed by TYV and CAP and all 3 pathologists on this study (STB, AN, CAP) trained TYV on morphologic evaluation). Hematoxylin and eosin stained sections (Emory Winship Pathology Core) of Swiss roll mounts of entire mouse colons were assessed for the percentage of the mucosa containing ulceration (0–4), crypt epithelial injury/damage (0–4), and infiltrate leukocytes masses (0–4). The spontaneous disease activity index included the average percentage of these three scoring parameters.

### Dextran Sodium Sulfate (DSS)-Induced Colitis

DSS (molecular mass, 36–50 kDa; MP Biomedicals, Solon, OH) was dissolved in purified water and administered to mice orally at 2.5% weight/volume. Mice were allowed free access to food and drinking water containing DSS from day 0 until day 7, and DSS was withdrawn to allow recovery from colitis for an additional 7 days. Daily clinical assessment of DSS-treated animals included evaluation of stool consistency (hard = 0; soft = 2; diarrhea = 4), detection of blood in stool (negative = 0; positive = 2; macroscopic = 4), and body weight loss measurements (no loss = 0; 1–5% loss = 1; 5–10% loss = 2; 10–20% loss = 3; >20% loss = 4). DSS-treated recipient mice individual scores were attributed for each one of these parameters and a disease activity index ranging from 0 to 4 was calculated by averaging all 3 scores. Remaining mice were euthanized on day 14 and colons were collected for further analysis.

### BM Transplantation to Generate Hematopoietic Chimeras

BM cells were isolated from 8 to 12 week old WT and *Gab2/3<sup>-/-</sup>* mice (*CD45.2<sup>+</sup>*) and were then transplanted by intravenous injection of about  $1 \times 10^7$  cells into lethally-irradiated (1,100 rads; *Cs<sup>137</sup>* source) BoyJ (*CD45.1*) recipient mice at a ratio of 1–2 donor equivalents (both hind limbs) per five recipients. Body weights were documented before and after transplantation and monitored bi-weekly for weight loss. Mice were monitored for 11 weeks and colons were collected for histological analysis. In some experiments, BM isolated from 8 to 12 week old BoyJ mice were transplanted into lethally irradiated either WT or *Gab2/3<sup>-/-</sup>* recipient mice. Three months after transplantation, the percentage of donor engraftment was analyzed by flow cytometry using mouse peripheral blood following staining with antibodies to multiple hematopoietic lineage markers (*CD8*, *CD4*, *B220*, *Gr-1*, *Ter119*). Colons were also collected for histological analysis.

### Newborn Injections

Pups generated from *Gab2<sup>+/-</sup>Gab3<sup>-</sup> × Gab2<sup>-/-</sup>Gab3<sup>-/-</sup>* mice were injected intraperitoneally with  $1 \times 10^7$  *CD45.1* congenic positive or GFP transgenic mouse BM cells 1–2 days after birth. At 4 weeks of age, the newly weaned mice were genotyped for *Gab2* and *Gab3*. At 16 weeks following injection, the mice were analyzed by flow cytometry of the peripheral blood leukocytes for engraftment with *CD45.1* congenic or GFP positive donor cells. The colon was also collected for histology analysis.

### BM-Derived Macrophage Culture

BM-derived macrophages (BMDM) were prepared using 8–12 week old WT, *Gab2<sup>-/-</sup>*, *Gab3<sup>-/-</sup>*, and *Gab2/3<sup>-/-</sup>* mice. Briefly, mice were sacrificed and tibia and femurs were collected. Using a 22-gauge needle marrow was flushed and resuspended in PBS containing 2% FBS. Samples were centrifuged at 1,200 rpm for 8 min, 4°C, and the supernatant was removed. Red blood cells were lysed using a sterile-filtered (0.22 μm) hypotonic solution (155 mM *NH<sub>4</sub>Cl*, 12 mM *NaHCO<sub>3</sub>*, 0.1 mM *EDTA*) and cell mixtures were filtered using a 40 μm cell strainer followed by centrifugation as described above. Cells were resuspended in complete Dulbecco's Modified Eagle Medium (DMEM). Cells were supplemented with 30% L929 conditioned media and incubated for 6 days. Additional feedings were performed at day 3 of culture. All experiments in this study were conducted using *CD11b<sup>+</sup>/F4/80<sup>+</sup>* mature macrophages as confirmed by flow cytometry.

### T-cell Expansion and IL-2 Stimulation

Twenty-four well plates were coated in PBS with 1 μg/ml anti-*CD3* and 0.5 μg/ml anti-*CD28* at 4°C overnight, and then the plates were used for cell culture after washing and blocking. The fresh mouse spleen single cell suspension was adjusted to a concentration of  $1 \times 10^6$  cells/mL in RPMI 1640 with 10 ng/ml of *IL-2*, and added into the pre-coated plates. After 3 days culture, cells were harvested and washed with RPMI 1640, and re-cultured in *IL-2* (10 ng/mL) at  $2 \times 10^5$  cells/mL in new plates for another 3 days. Cells were counted and stained with different

T-cell surface markers (CD4, CD8, CD62L, and CD44) at day 3 and day 6 post culture to check the expansion of T-cells. The IL-2 cultured cells were further collected, washed with PBS, and then starved in complete RPMI 1640 media containing 1% FBS for 5 h. After 5 h starvation, cells were left unstimulated or re-stimulated with 10 ng/mL of IL-2 for 5, 15, or 40 min. Protein samples were collected and Western blot was performed as described in the section Materials and Methods.

## RNA Isolation and Real-Time Quantitative PCR

To examine the effects of Gabs on mRNA expression of inflammatory cytokines in WT, Gab2<sup>-/-</sup>, Gab3<sup>-/-</sup>, and Gab2/3<sup>-/-</sup> BMDM cells, total cellular RNA was extracted from  $3 \times 10^6$  cells using Trizol reagent (Invitrogen, Carlsbad, CA, U.S.A) according to the manufacturer's protocol and cDNA was synthesized from 1.0  $\mu$ g of RNA using the high capacity cDNA reverse transcriptase kit protocol (Applied Biosystems, Foster City, CA). Real-time PCR was conducted using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA) and amplification was performed on a 7500 Real-time PCR instrument (Applied Biosystems, Foster City, CA). Inflammatory target genes were examined and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

## Western Blot Analysis

Cells were treated with 100 ng/ml of LPS for the indicated time periods. Whole cell lysates were collected from BMDM and solubilized proteins were separated by 10% SDS-PAGE, transferred to PVDF membrane (Bio-Rad, Hercules, CA), and detected by immunoblotting with specific primary antibodies and IRDye 800CW or IRDye 680RD secondary antibody with the Odyssey Imaging System (LI-COR Biosciences, Lincoln, NE).

## Cytokine Protein Production Measured by Luminex Assay

Briefly,  $1 \times 10^6$  BMDMs were plated and treated for 12 h with 100 ng/ml LPS ( $\gamma$ -irradiated, BioXtra, from E. coli O111:B4, Sigma). After centrifugation, supernatants were collected, frozen, and used for Luminex assay. To measure TNF $\alpha$ , and IFN- $\gamma$  protein secretion, Luminex assay was performed using the Invitrogen Luminex Cytokine Mouse 10-plex Panel following the manufacturers' protocol (Invitrogen, Carlsbad, CA, USA) and using the Luminex 100 system (Luminex Corp., Austin, TX).

## Colon Organ Tissue Culture

Freshly isolated mouse colon was washed twice (15 min each) with PBS, 3 mm length colon was cut, then weighed and placed into 48-well plate with 500  $\mu$ l IMEM with 5% FBS and cultured for 24 h. The supernatant was collected, frozen, and used for Luminex assay using the Invitrogen Luminex Cytokine Mouse 10-plex Panel following the manufacturers' protocol (Invitrogen, Carlsbad, CA).

## Isolation of Macrophages, IELs, and LPLs From Mouse Colon

Mouse colon macrophages were isolated using the protocol (46). Briefly, the colon was cut open longitudinally using scissors and fecal contents were washed off along with mucus from the colon lumen using Ca<sup>2+</sup>/Mg<sup>2+</sup>-free (CMF) PBS at room temperature. Then, the colon was cut into approximately 1.5 cm pieces and placed into 50 mL conical tubes with 30 mL of pre-warmed CMF Hank's balanced salt solution (HBSS) with 5% FBS and 2 mM EDTA, and shaken at 250 rpm for 20 min at 37°C, followed by a repeated wash. Colon pieces (1.5 cm) were recovered and washed, followed by mincing and digestion in 20 mL of collagenase solution (1.5 mg/mL type VIII collagenase dissolved in pre-warmed CMF HBSS/FBS with 40  $\mu$ g/mL of DNase I) at 200 rpm for 13–15 min at 37°C. It was filtered through a 100  $\mu$ m cell strainer directly into a 50 mL conical tube and centrifuge at 1,500 rpm for 5 min at 4°C and the cell pellet was resuspended in ice-cold CMF HBSS with 5% FBS. Finally CD45, CD11c, MHC II, CD11b, and F4/80 antibody staining was performed, followed by multi-color flow cytometry. Intraepithelial lymphocytes (IELs) and lamina propria lymphocytes (LPLs) from mouse colon were isolated using a Lamina Propria Dissociation Kit (Miltenyi Biotec Inc., Auburn CA) following the user's manual.

## Flow Cytometry Analyses of Tissue Immune Cell Numbers

To assess *in vivo* macrophage numbers, digested cells and splenocytes were stained with fluorescence conjugated antibodies against MHC II, CD45, F4/80, and CD11b (eBioscience, San Diego, CA). LIVE/DEAD staining (Thermo Fisher Scientific) was used to assay for cell viability determination at 405 nm excitation. For intracellular cytokine staining, freshly isolated IELs and splenocytes were incubated with 50 ng/ml PMA (Sigma), 750 ng/ml ionomycin (Sigma, St. Louis, MO) and 5  $\mu$ g/ml Brefeldin A (Biolegend, San Diego, CA) at 37°C for 4 h. Cells were first collected for surface staining with anti-CD8-BV650 (Biolegend, San Diego, CA), anti-CD62L-BV605 (Biolegend, San Diego, CA), anti-CD4-PE Cy7, and anti-CD44-APC (Thermo Fisher Scientific, Waltham, MA) antibodies, and then fixation and permeabilization were performed following the instructions from BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences, San Jose, CA). Intracellular staining for cytokines was detected with anti-IFN- $\gamma$ -PE, anti-TNF- $\alpha$ -FITC, and anti-IL-17-Percp Cy5.5 antibodies (Biolegend, San Diego, CA). Data were collected using a BD LSRII flow cytometer (BD Biosciences, San Jose, CA) and analyzed using FlowJo software (FlowJo, LLC, Ashland, OR).

## Adoptive Transfer of T-Cells and BMDMs

Details of antibodies used for T-cell sorting are listed in **Table S1**. WT or Gab2/3<sup>-/-</sup> spleens obtained from 8 to 12 week old mice were used for T-cell isolation. CD4<sup>+</sup> or CD8<sup>+</sup> cells were isolated by using either CD4<sup>+</sup> T-cell isolation kit or CD8<sup>+</sup> T-cells isolation kit (Miltenyi Biotec, Sunnyvale, CA). Naïve CD4 T-cells (CD4<sup>+</sup>CD45RB<sup>high</sup>) or naïve CD8<sup>+</sup> T-cells (CD44<sup>-</sup>CD62L<sup>+</sup>CD8<sup>+</sup>) were FACS-sorted. Naïve CD4<sup>+</sup> ( $8 \times$

$10^5$ ) or naïve CD8<sup>+</sup> ( $4 \times 10^5$ ) T-cells in 250  $\mu$ L 2% FBS in PBS were injected into 8–12 week old Rag2<sup>-/-</sup> mice by intraperitoneal injection. For some experiments, 8–12 week old Rag2<sup>-/-</sup> mice were injected with  $1 \times 10^6$  BMDMs in 250  $\mu$ L 2% FBS in PBS from either WT or Gab2/3<sup>-/-</sup> by IP injection first. Twenty-four hours later, those mice were transferred with  $8 \times 10^5$  FACS sorted WT naïve CD4<sup>+</sup> T-cells. Mice were monitored daily, weighed weekly, and euthanized at the end of 8 weeks after the T-cell transfer or earlier if meeting euthanasia criteria as described in this section. Colon length and weight were measured and colons were prepared for histology analysis.

## Statistical Analyses

Student's two tailed *t*-test was used to calculate *P*-values using the statistical function in the Microsoft excel and *F*-test was used to determine that the two groups had equal or unequal variances. For survival analysis, the log rank test was used to calculate *P*-values (SAS 9.4, SAS Institute, Cary, NC). For all statistical analyses, *P* < 0.05 were considered to be significant.

## RESULTS

### Gab2 and Gab3 Have Redundant Functions in Suppression of Spontaneous Colitis

To investigate whether Gab proteins play a redundant role in regulating the immune system, WT, Gab2<sup>-/-</sup>, Gab3<sup>-/-</sup>, and Gab2/3<sup>-/-</sup> mice were generated and monitored for at least 8 weeks for physiological changes and/or infection. Gab2/3<sup>-/-</sup> mice have modest reductions in peripheral blood hematology relative to WT and single knockout mice (Table 1).

As early as 8 weeks of age, rectal prolapse was observed in Gab2/3<sup>-/-</sup> mice and approximately 1/3 of the mice developed rectal prolapse (50/136) compared to none detected in control mice as determined during a representative 15-month observation period. Treatment with antibiotic at breeding or weaning stages ameliorated rectal prolapses indicating that resident microbiota are essential for the etiology of this experimental colitis (data not shown). Since diarrhea, intestinal mass/tumor, or colitis could increase the incidence of rectal prolapse in mice, colonic tissue was analyzed. Inflammation (Figure 1A) and muscular hypertrophy (Figure 1B) was observed on histology analysis in Gab2/3<sup>-/-</sup> mouse colon tissue compared to WT, Gab2<sup>-/-</sup>, and Gab3<sup>-/-</sup> control mice. The weights of the Gab2/3<sup>-/-</sup> colons were increased as well as the inflammation score and the spontaneous disease activity index (0–12 scale) (Figures 1C–E) compared with WT mice.

Interestingly, in addition to colon pathology, serum levels of amylase and globulin enzymes were elevated and albumin levels were decreased relative to WT resulting in a reduced albumin/globulin (A/G) ratio known to be associated with chronic inflammatory disease, including pancreatitis (Table S2). The pathology was tissue-specific since no gross abnormalities were observed outside of the gastrointestinal tract. Lipocalin-2 (Lcn-2) protein is a component of the innate immune response whose expression has been shown to be upregulated during infection. Fecal Lcn-2 has been demonstrated by others to be significantly increased in DSS colitis models potentially serving

as a sensitive and non-invasive approach to detect intestinal inflammation (43). To determine whether Lcn-2 would help to better predict colitis development, stool samples were collected and extremely elevated levels of Lcn-2 were observed in about 1/3 of the Gab2/3<sup>-/-</sup> mice compared to the very low expression in WT mice (Figure 1F). A comparison of WT, Gab2<sup>-/-</sup>, Gab3<sup>-/-</sup>, and Gab2/3<sup>-/-</sup> mice showed that maximal Lcn-2 increase was observed in double knockout mice (average of 26-fold), whereas mice with rectal prolapse had high Lcn-2 levels, but high Lcn-2 levels did not predict rectal prolapse.

Although Gab2/3<sup>-/-</sup> mice developed colitis-like phenotypes spontaneously, there was variation in controlling the rate of disease development as well as the severity of inflammation with age. To control for such variation in the spontaneous mouse model, age-matched young asymptomatic mice were orally administered DSS in the drinking water. DSS at 2.5% was given for 7 days followed by a 7 day recovery period. Clinical features of colitis, such as alterations in the intestines were assessed by endoscopy (Figure S1). Body weights and stool consistencies were monitored daily and scoring criteria were calculated in Gab2/3<sup>-/-</sup> mice (Figures 2A,B) compared to WT mice. Gab2/3<sup>-/-</sup> mice were extremely sensitive to DSS, resulting in death of 80% of Gab2/3<sup>-/-</sup> mice by day 14 compared to only 40% of WT mice (Figure 2C). Stool samples were collected during DSS treatment and increases in Lcn-2 were observed on day 3 suggesting increased sensitivity to treatments compared to WT mice (Figure S2). In addition, the DSS disease activity index (0–4 scale; averaged) showed faster onset of disease (Figure 2D) in Gab2/3<sup>-/-</sup> mice compared to WT mice. Histology measures showed increased inflammation in Gab2/3<sup>-/-</sup> mice on day 7 (Figure S3A) and day 14 (Figure S3B) relative to WT mice. Disease activity was assessed by scoring as described in the Methods. Greater ulceration, proliferative atypia, and goblet cell loss was observed in Gab2/3<sup>-/-</sup> mice (Figure S4) compared to WT mice. Altogether, these results suggest that Gab2/3<sup>-/-</sup> mice are more susceptible to colitis development than WT mice.

### Colitis Development in Gab2/3<sup>-/-</sup> Mice Is Hematopoietic Cell-Initiated and Associated With Increased Gut Cytokines and T-Cell Invasion

To understand the cellular mechanisms of colitis development in Gab2/3<sup>-/-</sup> mice, BM chimeras were generated using WT or Gab2/3<sup>-/-</sup> donors on the C57BL/6J background into lethally-irradiated WT BoyJ (CD45.1 congenic) recipient mice. After immune reconstitution by donor BM cells, chimeric mice were monitored for 11 weeks. High levels of donor CD45.2 multilineage engraftment were observed in both WT and Gab2/3<sup>-/-</sup> transplanted recipients 8 weeks after transplantation (Figure S5). Of the Gab2/3<sup>-/-</sup> BM transplant recipients, 6/15 died whereas none of the WT BM recipients died (Figure 3A). Rag2<sup>-/-</sup> recipients were also tested and all mice receiving Gab2/3<sup>-/-</sup> BM transplant died within 11 weeks after transplantation, whereas recipients of WT BM were all healthy with normal colon histology (data not

**TABLE 1** | Peripheral blood hematology of *Gab2*<sup>-/-</sup>, *Gab3*<sup>-/-</sup>, and *Gab2/3*<sup>-/-</sup> mice.

	WBC (10 <sup>3</sup> /μL)	LYM (10 <sup>3</sup> /μL)	MONO (10 <sup>3</sup> /μL)	GRAN (10 <sup>3</sup> /μL)	% LYM	% MONO	% GRAN	
WT (N = 37)	8.78 ± 2.28	7.14 ± 1.87	0.51 ± 0.19	1.13 ± 0.66	81.6 ± 6.4	5.2 ± 1.3	13.3 ± 5.3	
<i>Gab2</i> <sup>-/-</sup> (N = 8)	8.26 ± 2.16	7.13 ± 2.10	0.36 ± 0.09**	0.78 ± 0.07**	85.6 ± 3.8*	4.0 ± 1.0*	10.4 ± 3.0*	
<i>Gab3</i> <sup>-/-</sup> (N = 8)	8.84 ± 1.79	7.55 ± 1.64	0.46 ± 0.11	0.83 ± 0.17*	85.4 ± 2.3**	4.5 ± 0.9	10.1 ± 1.5**	
<i>Gab2/3</i> <sup>-/-</sup> (N = 16)	6.88 ± 2.65*	5.89 ± 2.59	0.35 ± 0.08***	0.63 ± 0.20***	82.6 ± 11.0	5.0 ± 1.8	12.4 ± 9.3	
	HCT (%)	MCV (fl)	RDW <sub>a</sub> (fl)	RDW %	HGB (g/dL)	MCHC (g/dL)	MCH (pg)	RBC (10 <sup>6</sup> /μL)
WT (N = 37)	47.2 ± 3.1	46.1 ± 1.4	31.3 ± 4.3	20.8 ± 2.9	16.5 ± 1.2	34.9 ± 1.2	16.1 ± 0.6	10.2 ± 0.7
<i>Gab2</i> <sup>-/-</sup> (N = 8)	48.6 ± 1.8	44.2 ± 0.6***	24.0 ± 0.4***	17.2 ± 0.4***	16.5 ± 0.5	34.0 ± 0.4***	15.0 ± 0.2***	11.0 ± 0.4***
<i>Gab3</i> <sup>-/-</sup> (N = 8)	44.4 ± 1.9**	45.2 ± 1.1	24.7 ± 0.8***	17.1 ± 0.4***	15.0 ± 0.5***	33.8 ± 0.4***	15.2 ± 0.4***	9.8 ± 0.5
<i>Gab2/3</i> <sup>-/-</sup> (N = 16)	45.9 ± 3.2	45.6 ± 2.5	27.0 ± 3.1***	18.5 ± 1.0***	15.7 ± 1.1*	34.2 ± 0.8*	15.6 ± 0.7*	10.1 ± 0.9

\**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001; unpaired *t*-test relative to WT; numbers of mice are indicated in the table. WBC, white blood cells; LYM, lymphocytes; MONO, monocytes; GRAN, granulocytes; HCT, hematocrit; MCV, mean corpuscular volume; RDW, Red cell distribution width; HGB, hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCH, mean corpuscular hemoglobin; RBC, red blood cells.

shown). Susceptible recipients of *Gab2/3*<sup>-/-</sup> BM showed a colitis phenotype (**Figure 3B**) resulting in forced euthanasia due to body weight decreases  $\geq 25\%$ . Interestingly, multiple ulcerations were present in most of the colon proximal region, with extensive epithelial damage, transmural inflammation, and adenocarcinoma in some recipients (**Figure S6**). Inversely, when WT donor BM cells were transplanted into lethally-irradiated *Gab2/3*<sup>-/-</sup> mice, engraftment with donor-derived WT cells (CD45.1<sup>+</sup>) was observed at a very high level (**Figure 3C**). *Gab2/3*<sup>-/-</sup> recipients did not develop disease and maintained normal colon epithelial crypt architecture (**Figure 3D**). Furthermore, in order to rule out potential radiation-induced damage to colon tissue, unconditioned *Gab2/3*<sup>-/-</sup> newborn recipients were transplanted and also showed a high percentage of donor engraftment after weaning (**Figure 3E**) and upon euthanasia at 5 months, 4/4 of the injected *Gab2/3*<sup>-/-</sup> mice showed normal colon histology (**Figure 3F**). With either lethal irradiation or no irradiation, both showed that engraftment of WT BM prevents disease. Therefore, colitis resulting from *Gab2/3* deficiency is hematopoietic cell-derived.


To identify specific immune cells which may have contributed to colitis in *Gab2/3*<sup>-/-</sup> mice, flow cytometry analyses were performed on colon, and spleen. Colon digestion was performed as described (46) and the antigen-presenting cell was identified by CD45 and MHC II co-expression. These cells were then analyzed for CD11b and F4/80 expression (**Figure 4A**). There was no change in the percentage of F4/80<sup>+</sup>CD11b<sup>+</sup> macrophages observed in the spleen or colon (**Figure 4B**) between *Gab2/3*<sup>-/-</sup> and WT groups. However, significantly increased percentages of CD4<sup>+</sup> and CD8<sup>+</sup> T-cells were observed in the colon but no differences in overall splenic T-cells was observed (**Figure 4C**) between *Gab2/3*<sup>-/-</sup> and WT. Comparable changes were observed in absolute numbers of cells (**Figure S7**). This result suggested that T-cells play a role in colitis development. Colon organ tissue from WT, or *Gab2/3*<sup>-/-</sup> mice with active disease, was cultured for 24 h and cytokines in the cultured medium were analyzed by Luminex assay. Inflammatory cytokines including

IFN $\gamma$  and TNF $\alpha$  were observed in *Gab2/3*<sup>-/-</sup> tissue cultures (**Figure 4D**). Notably, increases relative to WT mice were only observed in active disease (rectal prolapse and/or high Lcn-2). All mice utilized for these experiments had active disease but some of them developed rectal prolapse and others did not.

### ***Gab2/3*<sup>-/-</sup> Macrophages Are Pro-Inflammatory and Promote Colitis Following Adoptive Transfer into Immune-Deficient Hosts**

Increased inflammatory cytokines can be derived from macrophages which are key cells of the innate immune system with TLR4 receptors highly expressed on the cell surface. To investigate the role of macrophages in colitis, freshly isolated macrophages from WT and *Gab2/3*<sup>-/-</sup> BM cells and BMDMs from WT, *Gab2*<sup>-/-</sup>, *Gab3*<sup>-/-</sup>, and *Gab2/3*<sup>-/-</sup> mice were analyzed. The role of *Gab2/3* was first examined on cytokine production by macrophages. Macrophages were identified by CD11b and F4/80 co-staining and were analyzed for TNF $\alpha$  and IFN $\gamma$  expression as measured by intracellular flow cytometry. Primary *Gab2/3*<sup>-/-</sup> macrophages had elevated percentages (but not absolute numbers) of TNF $\alpha$  positive cells when compared to WT cells (**Figure 5A**). Second, BMDMs were cultured *in vitro* from *Gab2/3*<sup>-/-</sup> mice expanded and co-expressed CD11b and F4/80 (**Figure S8**). Analysis of culture-expanded *Gab2/3*<sup>-/-</sup> BMDMs screened for expression of pro-inflammatory cytokines by qRT-PCR showed elevated TNF $\alpha$  when compared to control or *Gab2*<sup>-/-</sup> or *Gab3*<sup>-/-</sup> cells (**Figure 5B**). No change was observed for IFN $\gamma$  expression (data not shown). After LPS treatment, secreted protein levels of both TNF $\alpha$  and IFN- $\gamma$  (**Figure 5C**) were significantly higher in BMDM conditioned media obtained from cells derived from *Gab2/3*<sup>-/-</sup> mice with rectal prolapse compared with WT.


The role of *Gab2/3* in macrophages during colitis development was next assessed, where  $1 \times 10^6$  LPS-polarized



BMDMs from *Gab2/3<sup>-/-</sup>* or WT were adoptively transferred into *Rag2<sup>-/-</sup>* mice first, and then sorted naïve WT CD4<sup>+</sup> T-cells were transferred 24 h later. From two independent experiments, weight loss was greater for the naïve CD4<sup>+</sup> T-cell transferred recipient mice treated with *Gab2/3<sup>-/-</sup>* BMDMs compared to the naïve CD4<sup>+</sup> T-cell transferred recipient mice treated with WT BMDMs (**Figure 5D**). At 2–5 weeks post-transfer, the *Gab2/3<sup>-/-</sup>* BMDM group had a significantly larger body weight loss when compared to the WT BMDM group at each time point. This indicates that *Gab2/3<sup>-/-</sup>* BMDMs were more potent at colitis induction than WT BMDMs. Although the colon weight/length ratio did not reach statistical significance, there was a trend (**Figure S9**).

### ***Gab2/3<sup>-/-</sup>* CD8<sup>+</sup> T-Cells Promote Colitis Following Adoptive Transfer into Immune-Deficient Hosts**

To test T-cell function *in vivo*, either naïve CD4<sup>+</sup> T-cells (CD4<sup>+</sup>CD45RB<sup>high</sup>) or naïve CD8<sup>+</sup> T-cells (CD8<sup>+</sup>CD44<sup>-</sup>CD62L<sup>+</sup>) were sorted from WT or *Gab2/3<sup>-/-</sup>* mice. Representative plots of T-cell flow cytometry gating and intracellular staining are shown in **Figure S10**. Upon transferring sorted naïve T-cells (**Figure S11**) into *Rag2<sup>-/-</sup>* mice by IP injection, both induced colitis as expected from the prior lack of antigen exposure. Weight loss for the transferred recipients was not different for transferred naïve *Gab2/3<sup>-/-</sup>* CD4<sup>+</sup> T-cells relative to WT (**Figure 6A**), but was greater




for naïve CD8<sup>+</sup> T-cells from *Gab2/3<sup>-/-</sup>* compared to WT (**Figure 6B**) (**Figure S12**). At 3–8 weeks post-transfer, the *Gab2/3<sup>-/-</sup>* group had significantly larger weight loss compared to the WT group at each time point and half of the *Gab2/3<sup>-/-</sup>* group mice required euthanasia due to more than 25% body weight reduction. The colon weight/length ratio was significantly increased in mice transferred with naïve *Gab2/3<sup>-/-</sup>* CD8<sup>+</sup> T-cells compared to WT but not for CD4<sup>+</sup> T-cells (**Figure 6C**). A representative gross colon comparison is shown in **Figure 6D** and illustrates the thickening, shortened length, and loss of normal stool consistency compared with WT. Histology revealed extensive colitis in both groups at the time of euthanasia according to defined weight loss criteria ( $\leq 75\%$  normal body weight) or at the termination of the experiment (week 8).


### Increased Numbers of Activated *Gab2/3<sup>-/-</sup>* CD8<sup>+</sup> Intraepithelial Effector Cells in the Colon

In addition to the regulatory and effector phenotypes, a balance between effector and memory phenotype characterizes the

immune response. The memory phenotype is characterized by high levels of expression of the activation marker CD44 and loss of CD62L. Virtual memory or memory phenotype cells are IL-15 dependent and mediate antigen non-specific bystander protective functions (48). Virtual memory cells decrease with age, leading to effector T-cell immunosenescence, changes in gut microbiota, and development of IBD in humans when exposed to antigens in the gut. Therefore, the immunophenotypes of *Gab2/3<sup>-/-</sup>* T-cells were examined. Although there were no changes in the percentage of CD4<sup>+</sup> and CD8<sup>+</sup> T-cells between WT and *Gab2/3<sup>-/-</sup>* mouse spleen, a highly consistent reduction of both the CD8<sup>+</sup>CD44<sup>+</sup>CD62L<sup>+</sup> and the CD8<sup>+</sup>CD122<sup>+</sup>CD49d<sup>-</sup> sub-populations was observed in *Gab2/3<sup>-/-</sup>* mice relative to WT, resulting in loss of memory phenotype T-cells which include regulatory CD8<sup>+</sup> T-cell populations (CD44<sup>+</sup>CD62L<sup>+</sup>CD122<sup>+</sup>) (**Figure 7A**). The CD44<sup>+</sup>CD62L<sup>-</sup> effector population of both splenic CD4<sup>+</sup> and CD8<sup>+</sup> T-cells was not changed (**Figure 7B**). Since T-cells can have both regulatory or effector functions and based on known markers for these subsets of T-cells (49–51), flow cytometry analyses were performed. Regulatory T-cells (Treg)



**FIGURE 3** | BM from Gab2/3<sup>-/-</sup> mice induces colitis in WT transplant recipients while reciprocal WT BM transplanted into Gab2/3<sup>-/-</sup> mice protects from colitis. **(A)** Diagram of WT or Gab2/3<sup>-/-</sup> BM transplantation into lethally-irradiated BoyJ recipients. Percentage of survival is shown as a Kaplan-Meier survival curve. Log rank test was used to calculate *P*-values (\*\**P* < 0.01). BM cells isolated from WT or Gab2/3<sup>-/-</sup> mice were injected into lethally-irradiated BoyJ mice (approximately  $1 \times 10^7$  cells/recipient). The results shown are the combination of 3 independent experiments with *N* = 15 for each group of mice. **(B)** Representative histology of WT and Gab2/3<sup>-/-</sup> BM transplanted mouse colon. Bar = 50 μm. **(C)** Diagram of WT BM (CD45.1) transplantation into lethally-irradiated WT or Gab2/3<sup>-/-</sup> recipients (CD45.2). The percentage of donor CD45.1 engraftment in the peripheral blood of WT BM transplanted WT or Gab2/3<sup>-/-</sup> mice. Experiments were repeated twice (*N* = 10 mice total for each group). **(D)** Representative normal colon histology in WT or Gab2/3<sup>-/-</sup> mice engrafted with WT BM donor cells. Bar = 100 μm. **(E)** Diagram of WT (CD45.1) or GFP transgenic BM transplantation into newborn mice on day 1 or 2 and mice were genotyped after weaning and donor engraftment was checked 16 weeks following transplantation. The percentage of donor engraftment in the peripheral blood of newborn recipients. One litter was injected with  $1 \times 10^7$  BoyJ BM cells and the other litter was injected with  $1 \times 10^7$  GFP transgenic BM cells. Totals of Gab2<sup>+/-</sup>Gab3<sup>-/-</sup> *N* = 9; Gab2<sup>-/-</sup>Gab3<sup>-/-</sup>, *N* = 4 mice (C57BL/6 background) were obtained and analyzed for evidence of long-term donor engraftment with CD45.1 congenic or GFP positive donor cells 16 weeks following injection. Data shown are the mean ± SD, \*\*\**P* < 0.001; unpaired *t*-test. **(F)** Representative colon histology of Gab2<sup>+/-</sup>Gab3<sup>-/-</sup> and Gab2<sup>-/-</sup>Gab3<sup>-/-</sup> mice. Mice were euthanized at the age of 5 months and colon histology was examined. Bar = 50 μm.




**FIGURE 4 |** *Gab2/3<sup>-/-</sup>* mice have increased macrophage and T-cell invasion of the colon and production of pro-inflammatory cytokines from colon extracts. **(A)** The flow cytometry gating strategy for F4/80 and CD11b<sup>+</sup> cells is shown. Dead cells were excluded using the LIVE/DEAD fixable aqua dead cells stain kit (Invitrogen, Carlsbad, CA) and subsequent analyses were gated on live cells. Antigen presenting cells (APCs) were selected by MHC II and CD45 double staining, and F4/80 and CD11b cells were gated on APCs. Data were acquired with a LSRII flow cytometer (BD Biosciences, USA) and analyzed with FlowJo Software. **(B)** The percentages of F4/80 and CD11b double positive cells in the colon and spleen are shown as the mean  $\pm$  SD ( $N = 4$ ). **(C)** The percentage of total CD4<sup>+</sup> and CD8<sup>+</sup> cells in lamina propria lymphocytes (LPL) after colon digestion with collagenase or in mouse splenocytes. Data are shown as the mean  $\pm$  SD ( $N = 4$ ,  $*P < 0.05$ ; unpaired *t*-test). **(D)** Freshly isolated mouse colon was used for colon organ culture with a 24-h collection time in IMEM with 5% FBS. Cytokines in cultured medium were measured using the mouse multiplex cytokine assay kit on a Luminex 100 instrument ( $N = 7$ , duplicated measurement). For comparison of WT vs. *Gab2/3<sup>-/-</sup>* groups; TNF- $\alpha$   $P = 0.06$  and for IFN $\gamma$   $*P = 0.02$ ; unpaired *t*-test.

are major suppressors of T-cell activation that are characterized by expression of CD25 and FoxP3 (52). To determine whether *Gab2/3* control CD4<sup>+</sup> Treg development, Tregs were quantified by flow cytometry and assessed for functional suppressor activity. The CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> population was not significantly changed and normal suppressor cell activity was maintained *in vitro* (Figures S13A,B). CD4<sup>+</sup> T-cell subsets were analyzed further for Th1, Th2, and Th17 differentiation in culture (Figures S13C-E) which are characterized by differential expression of intracellular cytokines. There were no

significant changes in CD4<sup>+</sup> T-cell development into Th1, Th2, and Th17.

T-cells are key cells of the adaptive immune system and have important effector functions in colitis through production of IFN $\gamma$ . To determine whether gut T-cells were also more activated at the site of antigen presentation, cells were isolated from either mesenteric lymph nodes (MLN) or large intestine including the intraepithelial lymphocytes (IEL) and lamina propria lymphocytes (LPL). IEL and LPL fractions were isolated using a commercially available kit (Miltenyi Biotec) and it




was important to analyze these cells since they are the tissue-resident lymphocytes acutely responsible for antigen-dependent responses in the gut and for maintaining colon immune homeostasis. All T-cell subsets were analyzed by flow cytometry immunophenotyping and cell cycle analysis using Ki67 staining. There was no significant difference regarding either the number of T-cells or their proliferation status in the LPL or MLN (Figure S14). However, strikingly there was significantly increased numbers of CD8 $^+$  T-cells in the IEL fraction relative to WT and these cells were increasingly proliferative (Ki67 $^+$ ) and expressed IL-17 (Figure 7C). Following stimulation with PMA/ionomycin *in vitro*, expression of IFN $\gamma$  and TNF $\alpha$  was detected in both CD4 $^+$  and CD8 $^+$  IELs (Figure 7D). Despite the higher induction of these cytokines in CD4 $^+$  IELs, the CD8 $^+$ IFN $\gamma$  $^+$  and CD8 $^+$ TNF $\alpha$  $^+$  fractions were more abundant relative to CD4 $^+$ IFN $\gamma$  $^+$  and CD4 $^+$ TNF $\alpha$  $^+$  fractions. Importantly, cytokine receptor expression levels were determined for IL-2R $\beta$  and the common  $\gamma$  chain and following IL-2 stimulation. No significant changes were observed, thus defective cytokine response was not due to altered receptor expression but rather altered signaling downstream of the receptor (data not shown).

## Dysregulated PI3K/Akt/mTOR Pathway Signaling in *Gab2/3<sup>-/-</sup>* Macrophages and T-Cells

Because adaptor proteins function directly at the level of protein-protein interactions and phosphorylation, to understand the molecular mechanism of signaling dysregulation in *Gab2/3<sup>-/-</sup>* T-cells and macrophages, isolated primary cultured splenic T-cells and BMDMs were utilized for Western blot analysis. Signaling pathways known to be modulated by Gab adaptor proteins were examined with a central focus on the PI3K/Akt/mTOR pathway (53, 54).

BMDMs were treated with 100 ng/ml LPS for up to 120 min, and *Gab2/3* deletion reduced phosphorylated PDK1 and phosphorylated AKT at the site of T308 relative to WT. *Gab2/3* deletion also severely reduced the amount of phosphorylated 4EBP1 (Ser65 and Thr37/46) (Figure 8A) compared to WT. *Gab2/3<sup>-/-</sup>* BMDMs also showed elevated p-NF $\kappa$ B p65 (Ser536) above that of WT BMDMs at the same time points. The T-cell response to IL-2 was initially marked by STAT5 phosphorylation in the double knockout splenic T-cells by Western analysis in addition to dysregulated PI3K/Akt/mTOR pathway (Figure 8B). In BMDMs, loss of mTORC1 did not increase mTORC2



**FIGURE 6** | Adoptively transferred naive  $Gab2^{-/-}$   $CD8^{+}$  T-cells are more colitogenic than WT  $CD8^{+}$  T-cells. **(A)** FACS sorted naive  $CD4^{+}CD45RB^{high}$  cells from WT or  $Gab2/3^{-/-}$  mice were transferred into  $Rag2^{-/-}$  mice via IP injection ( $8 \times 10^5$  cells/recipient). The weight change was monitored weekly. The results shown are combined from two independent experiments and are shown as the mean  $\pm$  SE, for  $N = 12$  from WT naive  $CD4$  and  $N = 16$  for  $Gab2/3^{-/-}$  naive  $CD4$ . There was no significant difference between WT and  $Gab2/3^{-/-}$  naive  $CD4^{+}$  cell-transferred mice (unpaired *t*-test). **(B)** FACS isolated naive  $CD8^{+}$  cells ( $CD8^{+}CD44^{-}CD62L^{+}$ ) from WT or  $Gab2/3^{-/-}$  mice were transferred into  $Rag2^{-/-}$  mice via IP injection ( $4 \times 10^5$  cells/recipient). The weight change was monitored weekly. The results shown are combined from 2 independent experiments and are shown as the mean  $\pm$  SE, for  $N = 10$  for WT and  $Gab2/3^{-/-}$  naive  $CD8$  (\* $P < 0.05$ , \*\* $P < 0.01$ , unpaired *t*-test). **(C)** The ratio of colon weight/length is shown. Upon euthanasia, the colon weight and length were measured (data are presented as the mean  $\pm$  SD,  $N = 8-9$  mice per group, \* $P < 0.05$ ; unpaired *t*-test). **(D)** Representative examples of the colon comparing WT to  $Gab2/3^{-/-}$  naive  $CD8^{+}$  T-cell adoptive transfer recipients.


activity. However, in T-cells the levels of p70S6K T389 and Akt S473 phosphorylation were increased relative to WT due to  $Gab2/3$  deletion (green arrows). These results suggest that increases in phosphorylation of p70S6K and Akt (S473) are due to mTORC2 consistent with a p70S6K-mediated loss of the mTORC1-mTORC2 negative feedback regulation in T-cells (55) (Figure 8C). Quantitation of the representative Western blot data is shown in Figure S15.

## DISCUSSION

In this study redundancy among  $Gab2$  and  $Gab3$  was uncovered through generation of novel double knockout mice. The results revealed previously unappreciated negative regulatory roles in prevention of spontaneous colitis and suppression of DSS-induced colitis. Mechanistic studies further defined that the cause of colitis was not due to deletion of  $Gab2/3$  in colon epithelium but rather due to dysregulated immune

cell biology. These findings provide greater understanding of the specific cell types that require Gab-mediated signaling and highlight how signaling dysregulation in naive  $CD8^{+}$  T-cells and macrophages cause colitis development. These insights might also lead to new treatment approaches in the future.


Previous studies have shown that in overexpression systems  $Gab2$  plays a role in T-cell receptor (TCR) signaling in Jurkat cells and mediates a feedback inhibitory PI3K signal during TCR activation (31, 32, 34). A  $Gab2$  proteomic study performed in Jurkat T-cells, confirmed that  $Gab2$  interacts with p85 and the 3 catalytic PI3K p110 subunits ( $\alpha$ ,  $\beta$ ,  $\delta$ ) (56). However, these prior studies were mainly performed in cell lines and focused on TCR signaling. One study of T-cell responses from  $129 \times C57BL/6$  mixed background mice showed increased responses to anti- $CD3/CD28$  in  $Gab2^{-/-}$  primary T-cells (33). However, in the studies reported here using extensively backcrossed  $C57BL/6$  mice, we did not observe effects of  $Gab2$  or  $Gab2/3$  deficiency on  $CD4^{+}$ , or  $CD8^{+}$  T-cell proliferation upon TCR activation



*in vitro*, or CD4<sup>+</sup> T-cell differentiation into Th1, Th2, or Th17 lineages *in vitro*. It is important to study *Gab2/3* signaling in these cells since they are major regulators of normal colon health. *Gab2* is phosphorylated following IL-2 and IL-15 stimulation of Jurkat cells, however a functional role in IL-2 signaling has not been established. These findings provide new information for the field and suggest new avenues for therapy by restoring *Gab* adaptor protein activity.

In T-cells, *Gab2* is induced downstream of IL-2 and IL-15 signaling (35). We found that *Gab2/3*<sup>-/-</sup> T-cell phenotypes are most similar to the *p110 $\delta$*  knockout mice that develop colitis. Although negative regulation of T-cell activation by *Gab2* has already been described through structure-function studies in Jurkat T-cells, no *in vivo* evidence of pathology has been reported

and there is little data generated in primary lymphocytes. Our data indicate that *Gab2* deficiency alone is insufficient and that additional loss of compensatory functions by *Gab3* is required to release T-cells from *Gab*-mediated repression sufficiently to cause pathology. CD8<sup>+</sup> T-cell profiling predicts prognosis in patients with Crohn's disease and ulcerative colitis (5, 57) and we observed the main contribution to colitis development was mediated by cytokine producing, proliferative, CD8<sup>+</sup> *Gab2/3*<sup>-/-</sup> T-cells in the intraepithelial compartment. In contrast, CD4<sup>+</sup> T-cells had a smaller numerical contribution. This specificity might derive from the fact that the highest *Gab3* expression occurs in memory CD8<sup>+</sup> T-cells and intraepithelial lymphocytes, although detailed analysis of the mucosal IEL sub-types involved will be a subject of future study. It is possible that *Gab2* is a key negative regulator of



the effector activity whereas *Gab3* plays a complementary role in promoting memory phenotype. With these dual roles, combined deletion would be expected to yield synergistic effects. *Gab2/3* function in IL-15 signaling was observed (data not shown) which may account for the reduced memory phenotype. Future studies of memory function in mice lacking *Gab2/3* are warranted. Interestingly, given the important role for IL-17/IL-23 signaling in colitis (58, 59), the observed increase in Tc17 cells lacking *Gab2/3* provides new insights toward not only *Gab2/3* regulation downstream of cytokines but also in regulation of important cytokine producing cells.

In macrophages, the absence of *Gab2* and *Gab3* led to a heightened response following TLR stimulation. The BMDMs were more pro-inflammatory, with high levels of IFN $\gamma$  and TNF $\alpha$  protein. A direct role for *Gab2/3* downstream of TLR signaling has not been described but identification of a role for *Gab2/3* downstream of TLR activation is novel. Inhibition

of PI3K also leads to enhanced LPS-mediated activation of JNK, p38, and ERK1/2 pathway in monocytes (60) therefore this was a major focus. This same study showed increased NF- $\kappa$ B pathway upon PI3K p110 $\gamma$  inhibition, consistent with our observation which shows increased NF- $\kappa$ B pathway. However, NF- $\kappa$ B activation has only been reported with knockout of PI3K class IB PI3K p101/p110 $\gamma$ , but *Gab* deficiency acts primarily via class IA PI3K p85/p110 $\alpha$ ,  $\beta$ ,  $\gamma$ . Notably, we found that deletion of *Gab2/3* in BMDMs reduced mTORC1 activation but without compensatory increased mTORC2 which can promote NF- $\kappa$ B activation (61, 62) in some cell types. mTOR activation is associated with macrophage polarization (63) and PI3K p110 $\gamma$  knockout/inhibition reprograms macrophages to an M1 phenotype (12) whereas PI3K p110 $\delta$  knockout reduces macrophage IL-10 production (8, 10). A positive role for *Gab1/2* in M2 macrophage polarization and idiopathic pulmonary fibrosis has been described (64). Similarly, mTORC2 promotes

M2 polarization (9, 65). In the BMDM adoptive transfer experiments, *Gab2/3*<sup>-/-</sup> BMDMs promoted inflammation relative to WT.

There are several common traits in *Gab2/3*<sup>-/-</sup> T-cells and macrophages with respect to the PI3K pathway. Both cell types showed the same reduction in PI3K/AKT<sup>T308</sup>/mTORC1/4EBP1 (marked by the red arrows in **Figure 8C**). Decreased mTORC1 and increased pSTAT5 is unique from other existing mouse models of PI3K, AKT, or mTOR deletion. Consistent with the observed mTOR dysregulation, T-stem cell memory (Tscm) accumulation and *Sca1* expression (data not shown) were consistent with reports of Raptor inhibition (17). In contrast, Rictor inhibits memory T-cells (20) and thus gain of mTORC2 activity would suppress memory phenotype cooperatively with decreased IL-15 responsiveness. Both Rictor and Raptor inhibition (18) increase memory T-cells because they are normally critical for glycolysis needed to drive effector cell function (19). PI3K p110 $\delta$  deletion results in inactivation of CD4<sup>+</sup> Tregs (66). Despite CD4<sup>+</sup> regulatory T-cells being major suppressors of immune cell activation, they were not reduced in the *Gab2/3*<sup>-/-</sup> mice. Therefore, the transplantable disease does not appear to be mediated through dysregulated regulatory CD4<sup>+</sup> T-cell number or function. This difference between the role of Gab expression compared with that of deletion of the p85-interacting subunits could be due to the concomitant increased activation of STAT5, a known regulator of CD4<sup>+</sup> Treg development through *Foxp3* expression. However, reduced CD8<sup>+</sup> Treg numbers was observed although the phenotypic [PD1<sup>+</sup>CD8<sup>+</sup> fraction (50, 67)] and functional significance has not yet been studied. Both *in vitro* and *in vivo* CD8<sup>+</sup> T-cell characterization revealed a major role for *Gab2/3* downstream of the IL-2R $\beta$  (CD122) for coordinating IL-2/IL-15 (35) but not IL-7 signaling. In addition to modulation of CD122 function (68), gain of pSTAT5 could also be an important contributor that drives effector proliferation (69) at the site of infection to sustain chronic colitis.

It is also interesting that we observed early invasive cancer in some of the transplant recipients but not in the knockout mice themselves. A major difference between these models is that the epithelial cells are WT in the BM transplant model and thus transformation of the epithelium may be more susceptible than epithelium lacking *Gab2/3*. This remains to be directly tested and future studies will be needed to examine roles for Gabs in epithelial barrier function or in transformation. Alternatively, irradiation itself could necessitate epithelial repair and proliferation that is essential for transformation or could induce genetic damage leading to mutations that drive epithelial transformation. In contrast, epithelial-specific knockout of SHP-2, a *Gab2* partner protein, causes barrier defects and colitis (70). *Gab2* overexpression is also a clinically significant biomarker for malignant invasion and metastasis of several cancers, including breast and gastric cancer (71–75). It is possible that loss of *Gab*-SHP-2 interaction could play a role in our model. We show in this study a major role for Gabs in mTORC1 activation in macrophages and T-cells, and mTORC1 is a major gastrointestinal cancer promoting signal in epithelium (76). Therefore, dual roles for Gabs

in mTORC1 activation in different tissues are possibly and could account for some of the differences we have observed between transplanted and non-transplanted mice in regard to epithelial transformation.

These studies did not examine the role of *Gab1* in immune cell function. However, we did find that *Gab1* levels are increased in *Gab2/3*<sup>-/-</sup> macrophages (data not shown) which suggests that *Gab1* might be part of a compensatory response to moderate the defects and could contribute to some mouse-to-mouse variation in addition to cage-specific microbiota. *Gab1* is also known to promote TLR3/4 and RIG-I mediated production of pro-inflammatory cytokines and type I interferon in primary macrophages and mouse embryonic fibroblasts (77) and to promote mTORC2 activation (78). Future studies that target *Gab1* in combination with *Gab2/3* may shed light on the combined role of all Gabs in regulation of immune cell activation and colitis development.

It is possible that human IBD involves changes in *Gab* family member expression within the T-cells and/or macrophages but a role for *Gab* dosage as a human IBD biomarker remains to be determined. Human CD8<sup>+</sup> T-cells are emerging as major mediators of human IBD and the identification of a key role for *Gab2/3* in suppression of T-cell and macrophage function, fills in major gaps in our understanding of how CD8<sup>+</sup> T-cells drive IBD. Furthermore, the *H. pylori* virulence factor *CagA* has been shown to protect against DSS-induced experimental colitis (79) and is inversely associated with human IBD (40) but no functional roles have been previously attributed to *Gab* adaptor proteins in promoting a healthy colon under normal physiological conditions. The findings of this study thus provide a deeper understanding of how *Gab2* and *Gab3* redundantly function to ultimately control CD8<sup>+</sup> T-cell and this finding could lead to new therapeutic avenues.

## DATA AVAILABILITY

All datasets generated for this study are included in the manuscript and/or the supplementary files.

## AUTHOR CONTRIBUTIONS

ZW, TV, WZ, YC, MM, GF, and HN performed experiments and analyzed the data. TV and SB performed pathology analyses. PH-G backcrossed *Gab3*<sup>-/-</sup> mice to C57BL/6 and provided them for this study. AN and CP provided advice and performed DSS experiments in their laboratory (HN). DW and RW provided advice and performed CD4<sup>+</sup> T-cell experiments in their laboratory (YC and GF). ZW, TV, RW, and KB wrote the manuscript. KB organized the study and performed colitis, macrophage, and CD8<sup>+</sup> T-cell experiments in his laboratory (ZW, TV, WZ, and MM).

## FUNDING

This work is supported by the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Emory University (KB) and NIH R01DK059380 (KB). We gratefully acknowledge the support of the Emory + Children's Department of Pediatrics Flow Cytometry and Immunology core facilities and the Emory Winship Pathology Core facility. Additional support was provided by AI079087 (DW), HL130724 (DW), DK072564 (CP), and DK055679 (AN).

## REFERENCES

- Murray PJ, Smale ST. Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. *Nat Immunol.* (2012) 13:916–24. doi: 10.1038/ni.2391
- Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. *Infect Immun.* (1998) 66:5224–31.
- Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. *Nat Rev Immunol.* (2003) 3:521–33. doi: 10.1038/nri1132
- Mizoguchi A. Animal models of inflammatory bowel disease. *Prog Mol Biol Transl Sci.* (2012) 105:263–320. doi: 10.1016/B978-0-12-394596-9.00009-3
- Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr EJ, Bredin F, et al. Gene expression profiling of CD8<sup>+</sup> T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. *J Clin Invest.* (2011) 121:4170–9. doi: 10.1172/JCI159255
- Lee I, Blom UM, Wang PI, Shim JE, Marcotte EM. Prioritizing candidate disease genes by network-based boosting of genome-wide association data. *Genome Res.* (2011) 21:1109–21. doi: 10.1101/gr.118992.110
- Gu H, Pratt JC, Burakoff SJ, Neel BG. Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. *Mol Cell.* (1998) 2:729–40. doi: 10.1016/S1097-2765(00)80288-9
- Uno JK, Rao KN, Matsuoka K, Sheikh SZ, Kobayashi T, Li F, et al. Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110delta. *Gastroenterology.* (2010) 139:1642–53.e6. doi: 10.1053/j.gastro.2010.07.008
- Festuccia WT, Pouliot P, Bakan I, Sabatini DM, Laplante M. Myeloid-specific Rictor deletion induces M1 macrophage polarization and potentiates *in vivo* pro-inflammatory response to lipopolysaccharide. *PLoS ONE.* (2014) 9:e95432. doi: 10.1371/journal.pone.0095432
- Steinbach EC, Kobayashi T, Russo SM, Sheikh SZ, Gipson GR, Kennedy ST, et al. Innate PI3K p110delta regulates Th1/Th17 development and microbiota-dependent colitis. *J Immunol.* (2014) 192:3958–68. doi: 10.4049/jimmunol.1301533
- Li X, Wang D, Chen Z, Lu E, Wang Z, Duan J, et al. Galphai1 and Galphai3 regulate macrophage polarization by forming a complex containing CD14 and Gab1. *Proc Natl Acad Sci USA.* (2015) 112:4731–6. doi: 10.1073/pnas.1503779112
- Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3Kgamma is a molecular switch that controls immune suppression. *Nature.* (2016) 539:437–42. doi: 10.1038/nature19834
- Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. *Nature.* (2009) 460:108–12. doi: 10.1038/nature08155
- Li Q, Rao RR, Araki K, Pollizzi K, Odunsi K, Powell JD, et al. A central role for mTOR kinase in homeostatic proliferation induced CD8<sup>+</sup> T cell memory and tumor immunity. *Immunity.* (2011) 34:541–53. doi: 10.1016/j.immuni.2011.04.006

## ACKNOWLEDGMENTS

We thank Chris Yun for helpful advice and PDK1 antibody. We thank Tim Denning, Duke Geem, Barry Imhoff, Heath Bradley, and Kimberly Herard for their technical support.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.00486/full#supplementary-material>

- Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory CD8<sup>+</sup> T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. *Immunity.* (2010) 32:67–78. doi: 10.1016/j.immuni.2009.10.010
- Rao RR, Li Q, Gubbels Bupp MR, Shrikant PA. Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8<sup>+</sup> T cell differentiation. *Immunity.* (2012) 36:374–87. doi: 10.1016/j.immuni.2012.01.015
- Scholz G, Jandus C, Zhang L, Grandclement C, Lopez-Mejia IC, Sonesson C, et al. Modulation of mTOR signalling triggers the formation of stem cell-like memory T cells. *EBioMedicine.* (2016) 4:50–61. doi: 10.1016/j.ebiom.2016.01.019
- Pollizzi KN, Patel CH, Sun IH, Oh MH, Waickman AT, Wen J, et al. mTORC1 and mTORC2 selectively regulate CD8<sup>+</sup> T cell differentiation. *J Clin Invest.* (2015) 125:2090–108. doi: 10.1172/jci77746
- Gubser PM, Bantug GR, Razik L, Fischer M, Dimeloe S, Hoenger G, et al. Rapid effector function of memory CD8<sup>+</sup> T cells requires an immediate-early glycolytic switch. *Nat Immunol.* (2013) 14:1064–72. doi: 10.1038/ni.2687
- Zhang L, Tschumi BO, Lopez-Mejia IC, Oberle SG, Meyer M, Samson G, et al. Mammalian target of rapamycin complex 2 controls CD8 T cell memory differentiation in a Foxo1-dependent manner. *Cell Rep.* (2016) 14:1206–17. doi: 10.1016/j.celrep.2015.12.095
- Gu H, Saito K, Klamann LD, Shen J, Fleming T, Wang Y, et al. Essential role for Gab2 in the allergic response. *Nature.* (2001) 412:186–90. doi: 10.1038/35084076
- Nishida K, Wang L, Morii E, Park SJ, Narimatsu M, Itoh S, et al. Requirement of Gab2 for mast cell development and KitL/c-Kit signaling. *Blood.* (2002) 99:1866–9. doi: 10.1182/blood.V99.5.1866
- Wada T, Nakashima T, Oliveira-dos-Santos AJ, Gasser J, Hara H, Schett G, et al. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. *Nat Med.* (2005) 11:394–9. doi: 10.1038/nm1203
- Yu M, Luo J, Yang W, Wang Y, Mizuki M, Kanakura Y, et al. The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. *J Biol Chem.* (2006) 281:28615–26. doi: 10.1074/jbc.M603742200
- Zhang Y, Diaz-Flores E, Li G, Wang Z, Kang Z, Haviernikova E, et al. Abnormal hematopoiesis in Gab2 mutant mice. *Blood.* (2007) 110:116–24. doi: 10.1182/blood-2006-11-060707
- Seiffert M, Custodio JM, Wolf I, Harkey M, Liu Y, Blattman JN, et al. Gab3-deficient mice exhibit normal development and hematopoiesis and are immunocompetent. *Mol Cell Biol.* (2003) 23:2415–24. doi: 10.1128/MCB.23.7.2415-2424.2003
- Wolf I, Jenkins BJ, Liu Y, Seiffert M, Custodio JM, Young P, et al. Gab3, a new DOS/Gab family member, facilitates macrophage differentiation. *Mol Cell Biol.* (2002) 22:231–44. doi: 10.1128/MCB.22.1.231-244.2002
- Bezman NA, Kim CC, Sun JC, Min-Oo G, Hendricks DW, Kamimura Y, et al. Molecular definition of the identity and activation of natural killer cells. *Nat Immunol.* (2012) 13:1000–9. doi: 10.1038/ni.2395
- Best JA, Blair DA, Knell J, Yang E, Mayya V, Doedens A, et al. Transcriptional insights into the CD8<sup>+</sup> T cell response to infection and memory T cell formation. *Nat Immunol.* (2013) 14:404–12. doi: 10.1038/ni.2536

30. Nishida K, Yoshida Y, Itoh M, Fukada T, Ohtani T, Shirogane T, et al. Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors. *Blood*. (1999) 93:1809–16.
31. Pratt JC, Igras VE, Maeda H, Baksh S, Gelfand EW, Burakoff SJ, et al. Cutting edge: gab2 mediates an inhibitory phosphatidylinositol 3'-kinase pathway in T cell antigen receptor signaling. *J Immunol*. (2000) 165:4158–63. doi: 10.4049/jimmunol.165.8.4158
32. Yamasaki S, Nishida K, Hibi M, Sakuma M, Shiina R, Takeuchi A, et al. Docking protein Gab2 is phosphorylated by ZAP-70 and negatively regulates T cell receptor signaling by recruitment of inhibitory molecules. *J Biol Chem*. (2001) 276:45175–83. doi: 10.1074/jbc.M105384200
33. Yamasaki S, Nishida K, Sakuma M, Berry D, McGlade CJ, Hirano T, et al. Gads/Grb2-mediated association with LAT is critical for the inhibitory function of Gab2 in T cells. *Mol Cell Biol*. (2003) 23:2515–29. doi: 10.1128/MCB.23.7.2515-2529.2003
34. Parry RV, Whittaker GC, Sims M, Edmead CE, Welham MJ, Ward SG. Ligation of CD28 stimulates the formation of a multimeric signaling complex involving grb-2-associated binder 2 (gab2), SRC homology phosphatase-2, and phosphatidylinositol 3-kinase: evidence that negative regulation of CD28 signaling requires the gab2 pleckstrin homology domain. *J Immunol*. (2006) 176:594–602. doi: 10.4049/jimmunol.176.1.594
35. Gadina M, Sudarshan C, Visconti R, Zhou YJ, Gu H, Neel BG, et al. The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. *J Biol Chem*. (2000) 275:26959–66. doi: 10.1074/jbc.M004021200
36. Hatakeyama M. *Helicobacter pylori* CagA—a potential bacterial oncoprotein that functionally mimics the mammalian Gab family of adaptor proteins. *Microbes Infect*. (2003) 5:143–50. doi: 10.1016/S1286-4579(02)00085-0
37. Botham CM, Wandler AM, Guillemin K. A transgenic *Drosophila* model demonstrates that the *Helicobacter pylori* CagA protein functions as a eukaryotic Gab adaptor. *PLoS Pathog*. (2008) 4:e1000064. doi: 10.1371/journal.ppat.1000064
38. Simister PC, Feller SM. Order and disorder in large multi-site docking proteins of the Gab family—implications for signalling complex formation and inhibitor design strategies. *Mol Biosyst*. (2012) 8:33–46. doi: 10.1039/c1mb05272a
39. Sonnenberg A, Genta RM. Low prevalence of *Helicobacter pylori* infection among patients with inflammatory bowel disease. *Aliment Pharmacol Ther*. (2012) 35:469–76. doi: 10.1111/j.1365-2036.2011.04969.x
40. Arnold IC, Muller A. *Helicobacter pylori*: does gastritis prevent colitis? *Inflamm Intest Dis*. (2016) 1:102–12. doi: 10.1159/000445985
41. Lord AR, Simms LA, Hanigan K, Sullivan R, Hobson P, Radford-Smith GL. Protective effects of *Helicobacter pylori* for IBD are related to the cagA-positive strain. *Gut*. (2018) 67:393–4. doi: 10.1136/gutjnl-2017-313805
42. Lina TT, Alzahrani S, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. Immune evasion strategies used by *Helicobacter pylori*. *World J Gastroenterol*. (2014) 20:12753–66. doi: 10.3748/wjg.v20.i36.12753
43. Chassaing B, Srinivasan G, Delgado MA, Young AN, Gewirtz AT, Vijay-Kumar M. Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. *PLoS ONE*. (2012) 7:e44328. doi: 10.1371/journal.pone.0044328
44. Nava P, Koch S, Laukoetter MG, Lee WY, Kolegraff K, Capaldo CT, et al. Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. *Immunity*. (2010) 32:392–402. doi: 10.1016/j.immuni.2010.03.001
45. Khounlotham M, Kim W, Peatman E, Nava P, Medina-Contreras O, Addis C, et al. Compromised intestinal epithelial barrier induces adaptive immune compensation that protects from colitis. *Immunity*. (2012) 37:563–73. doi: 10.1016/j.immuni.2012.06.017
46. Geem D, Medina-Contreras O, Kim W, Huang CS, Denning TL. Isolation and characterization of dendritic cells and macrophages from the mouse intestine. *J Vis Exp*. (2012) 63:e4040. doi: 10.3791/4040
47. Friedman DJ, Kunzli BM, Yi AR, Sevigny J, Berberat PO, Enyoyji K, et al. From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. *Proc Natl Acad Sci USA*. (2009) 106:16788–93. doi: 10.1073/pnas.0902869106
48. White JT, Cross EW, Burchill MA, Danhorn T, McCarter MD, Rosen HR, et al. Virtual memory T cells develop and mediate bystander protective immunity in an IL-15-dependent manner. *Nat Commun*. (2016) 7:11291. doi: 10.1038/ncomms11291
49. Sekiya T, Yoshimura A. *In vitro* Th differentiation protocol. *Methods Mol Biol*. (2016) 1344:183–91. doi: 10.1007/978-1-4939-2966-5\_10
50. Liu H, Wang Y, Zeng Q, Zeng YQ, Liang CL, Qiu F, et al. Suppression of allograft rejection by CD8<sup>+</sup>CD122<sup>+</sup>PD-1<sup>+</sup> Tregs is dictated by their Fas ligand-initiated killing of effector T cells versus Fas-mediated own apoptosis. *Oncotarget*. (2017) 8:24187–95. doi: 10.18632/oncotarget.15551
51. Chen Y, Zander R, Khatun A, Schauder DM, Cui W. Transcriptional and epigenetic regulation of effector and memory CD8 T cell differentiation. *Front Immunol*. (2018) 9:2826. doi: 10.3389/fimmu.2018.02826
52. Plitas G, Rudensky AY. Regulatory T cells: differentiation and function. *Cancer Immunol Res*. (2016) 4:721–5. doi: 10.1158/2326-6066.cir-16-0193
53. Jung S, Gamez-Diaz L, Proietti M, Grimbacher B. “Immune TOR-opathies,” a novel disease entity in clinical immunology. *Front Immunol*. (2018) 9:966. doi: 10.3389/fimmu.2018.00966
54. O'Donnell JS, Massi D, Teng MWL, Mandala M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. *Semin Cancer Biol*. (2018) 48:91–103. doi: 10.1016/j.semcancer.2017.04.015
55. Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. *Nat Cell Biol*. (2013) 15:1340–50. doi: 10.1038/ncb2860
56. Osinalde N, Sanchez-Quiles V, Blagoev B, Kratchmarova I. Changes in Gab2 phosphorylation and interaction partners in response to interleukin (IL)-2 stimulation in T-lymphocytes. *Sci Rep*. (2016) 6:23530. doi: 10.1038/srep23530
57. Ventham NT, Kennedy NA, Adams AT, Kalla R, Heath S, O'Leary KR, et al. Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. *Nat Commun*. (2016) 7:13507. doi: 10.1038/ncomms13507
58. Catana CS, Berindan Neagoe I, Cozma V, Magdas C, Tabaran F, Dumitrascu DL. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. *World J Gastroenterol*. (2015) 21:5823–30. doi: 10.3748/wjg.v21.i19.5823
59. Regner EH, Ohri N, Stahly A, Gerich ME, Fennimore BP, Ir D, et al. Functional intraepithelial lymphocyte changes in inflammatory bowel disease and spondyloarthritis have disease specific correlations with intestinal microbiota. *Arthritis Res Ther*. (2018) 20:149. doi: 10.1186/s13075-018-1639-3
60. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. *J Biol Chem*. (2002) 277:32124–32. doi: 10.1074/jbc.M203298200
61. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. *Cancer Discov*. (2011) 1:524–38. doi: 10.1158/2159-8290.cd-11-0124
62. Choi YJ, Moon KM, Chung KW, Jeong JW, Park D, Kim DH, et al. The underlying mechanism of proinflammatory NF-kappaB activation by the mTORC2/Akt/IKKalpha pathway during skin aging. *Oncotarget*. (2016) 7:52685–94. doi: 10.18632/oncotarget.10943
63. Byles V, Covarrubias AJ, Ben-Sahra I, Lamming DW, Sabatini DM, Manning BD, et al. The TSC-mTOR pathway regulates macrophage polarization. *Nat Commun*. (2013) 4:2834. doi: 10.1038/ncomms3834
64. Guo X, Li T, Xu Y, Xu X, Zhu Z, Zhang Y, et al. Increased levels of Gab1 and Gab2 adaptor proteins skew interleukin-4 (IL-4) signaling toward M2 macrophage-driven pulmonary fibrosis in mice. *J Biol Chem*. (2017) 292:14003–15. doi: 10.1074/jbc.M117.802066
65. Hallowell RW, Collins SL, Craig JM, Zhang Y, Oh M, Illei PB, et al. mTORC2 signalling regulates M2 macrophage differentiation in response to helminth infection and adaptive thermogenesis. *Nat Commun*. (2017) 8:14208. doi: 10.1038/ncomms14208
66. Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. *Nature*. (2014) 510:407–11. doi: 10.1038/nature13444
67. Dai H, Wan N, Zhang S, Moore Y, Wan F, Dai Z. Cutting edge: programmed death-1 defines CD8<sup>+</sup>CD122<sup>+</sup> T cells as regulatory versus

- memory T cells. *J Immunol.* (2010) 185:803–7. doi: 10.4049/jimmunol.1000661
68. Castro I, Yu A, Dee MJ, Malek TR. The basis of distinctive IL-2- and IL-15-dependent signaling: weak CD122-dependent signaling favors CD8<sup>+</sup> T central-memory cell survival but not T effector-memory cell development. *J Immunol.* (2011) 187:5170–82. doi: 10.4049/jimmunol.1003961
  69. Hand TW, Cui W, Jung YW, Sefik E, Joshi NS, Chandele A, et al. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. *Proc Natl Acad Sci USA.* (2010) 107:16601–6. doi: 10.1073/pnas.1003457107
  70. Coulombe G, Leblanc C, Cagnol S, Maloum F, Lemieux E, Perreault N, et al. Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice. *Mol Cell Biol.* (2013) 33:2275–84. doi: 10.1128/MCB.00043-13
  71. Daly RJ, Gu H, Parmar J, Malaney S, Lyons RJ, Kairouz R, et al. The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. *Oncogene.* (2002) 21:5175–81. doi: 10.1038/sj.onc.1205522
  72. Bentires-Alj M, Gil SG, Chan R, Wang ZC, Wang Y, Imanaka N, et al. A role for the scaffolding adapter GAB2 in breast cancer. *Nat Med.* (2006) 12:114–21. doi: 10.1038/nm1341
  73. Ke Y, Wu D, Princen F, Nguyen T, Pang Y, Lesperance J, et al. Role of Gab2 in mammary tumorigenesis and metastasis. *Oncogene.* (2007) 26:4951–60. doi: 10.1038/sj.onc.1210315
  74. Lee SH, Jeong EG, Nam SW, Lee JY, Yoo NJ, Lee SH. Increased expression of Gab2, a scaffolding adaptor of the tyrosine kinase signalling, in gastric carcinomas. *Pathology.* (2007) 39:326–9. doi: 10.1080/00313020701329773
  75. Bennett HL, Brummer T, Jeanes A, Yap AS, Daly RJ. Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis. *Oncogene.* (2008) 27:2693–704. doi: 10.1038/sj.onc.1210928
  76. Thiem S, Pierce TP, Palmieri M, Putoczki TL, Buchert M, Preaudet A, et al. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. *J Clin Invest.* (2013) 123:767–81. doi: 10.1172/JCI65086
  77. Zheng Y, An H, Yao M, Hou J, Yu Y, Feng G, et al. Scaffolding adaptor protein Gab1 is required for TLR3/4- and RIG-I-mediated production of proinflammatory cytokines and type I IFN in macrophages. *J Immunol.* (2010) 184:6447–56. doi: 10.4049/jimmunol.0901750
  78. Chang CH, Chan PC, Li JR, Chen CJ, Shieh JJ, Fu YC, et al. Gab1 is essential for membrane translocation, activity and integrity of mTORCs after EGF stimulation in urothelial cell carcinoma. *Oncotarget.* (2015) 6:1478–89. doi: 10.18632/oncotarget.2756
  79. Zhang H, Dai Y, Liu Y, Wu T, Li J, Wang X, et al. *Helicobacter pylori* colonization protects against chronic experimental colitis by regulating Th17/Treg balance. *Inflamm Bowel Dis.* (2018) 24:1481–92. doi: 10.1093/ibd/izy107

**Conflict of Interest Statement:** KB has a financial interest in Valhalla Scientific Editing Service, LLC.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Wang, Vaughan, Zhu, Chen, Fu, Medrzycki, Nishio, Bunting, Hankey-Giblin, Nusrat, Parkos, Wang, Wen and Bunting. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.